MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, today presented new pre-clinical data for its lead RNA activation program for the treatment of sickle cell disease, ...
CRISPR is turned into a drug delivery system that helps recreate fetal hemoglobin, which then changes into red blood cells. Because the gene mutation for sickle cell disease is not found in fetal ...